KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Biogen (BIIB) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Biogen (BIIB) over the last 17 years, with Q4 2025 value amounting to 24.19%.

  • Biogen's EBIT Margin fell 123000.0% to 24.19% in Q4 2025 from the same period last year, while for Dec 2025 it was 8.57%, marking a year-over-year decrease of 43900.0%. This contributed to the annual value of 8.57% for FY2025, which is 43900.0% down from last year.
  • Biogen's EBIT Margin amounted to 24.19% in Q4 2025, which was down 123000.0% from 4.62% recorded in Q3 2025.
  • Biogen's 5-year EBIT Margin high stood at 36.15% for Q1 2021, and its period low was 31.65% during Q3 2023.
  • For the 5-year period, Biogen's EBIT Margin averaged around 4.62%, with its median value being 3.0% (2023).
  • As far as peak fluctuations go, Biogen's EBIT Margin surged by 330700bps in 2021, and later tumbled by -675900bps in 2023.
  • Quarter analysis of 5 years shows Biogen's EBIT Margin stood at 21.48% in 2021, then tumbled by -94bps to 1.29% in 2022, then plummeted by -1159bps to 13.69% in 2023, then grew by 13bps to 11.9% in 2024, then plummeted by -103bps to 24.19% in 2025.
  • Its EBIT Margin was 24.19% in Q4 2025, compared to 4.62% in Q3 2025 and 5.25% in Q2 2025.